Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
26.62
-0.08 (-0.30%)
Jan 22, 2026, 3:54 PM EST - Market open
Arcutis Biotherapeutics Revenue
Arcutis Biotherapeutics had revenue of $99.22M in the quarter ending September 30, 2025, with 121.69% growth. This brings the company's revenue in the last twelve months to $317.93M, up 129.21% year-over-year. In the year 2024, Arcutis Biotherapeutics had annual revenue of $196.54M with 229.74% growth.
Revenue (ttm)
$317.93M
Revenue Growth
+129.21%
P/S Ratio
10.62
Revenue / Employee
$929,617
Employees
342
Market Cap
3.26B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 196.54M | 136.94M | 229.74% |
| Dec 31, 2023 | 59.61M | 55.92M | 1,517.09% |
| Dec 31, 2022 | 3.69M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Catalyst Pharmaceuticals | 578.20M |
| Tarsus Pharmaceuticals | 366.10M |
| IDEAYA Biosciences | 214.83M |
| Viridian Therapeutics | 70.79M |
| Liquidia | 69.22M |
| Beam Therapeutics | 55.70M |
| Centessa Pharmaceuticals | 15.00M |
| Xenon Pharmaceuticals | 7.50M |
ARQT News
- 1 day ago - Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions - GlobeNewsWire
- 10 days ago - Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones - GlobeNewsWire
- 6 weeks ago - Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri - GlobeNewsWire
- 6 weeks ago - Arcutis Biotherapeutics: The Earnings Inflection Has Arrived - Seeking Alpha
- 2 months ago - FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 - GlobeNewsWire
- 2 months ago - PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors - Seeking Alpha
- 2 months ago - Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis - GlobeNewsWire
- 2 months ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire